GB9321162D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB9321162D0
GB9321162D0 GB939321162A GB9321162A GB9321162D0 GB 9321162 D0 GB9321162 D0 GB 9321162D0 GB 939321162 A GB939321162 A GB 939321162A GB 9321162 A GB9321162 A GB 9321162A GB 9321162 D0 GB9321162 D0 GB 9321162D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
halo
cyano
hydroxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939321162A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co PLC filed Critical Boots Co PLC
Priority to GB939321162A priority Critical patent/GB9321162D0/en
Publication of GB9321162D0 publication Critical patent/GB9321162D0/en
Priority to IN982MA1994 priority patent/IN179169B/en
Priority to EP94929537A priority patent/EP0723546B1/en
Priority to CZ961069A priority patent/CZ106996A3/cs
Priority to RU96108927A priority patent/RU2136684C1/ru
Priority to JP7511287A priority patent/JPH09503771A/ja
Priority to DE69422724T priority patent/DE69422724T2/de
Priority to PT94929537T priority patent/PT723546E/pt
Priority to PL94313970A priority patent/PL177920B1/pl
Priority to UA96041428A priority patent/UA42738C2/uk
Priority to ES94929537T priority patent/ES2142413T3/es
Priority to IL111259A priority patent/IL111259A/en
Priority to AT94929537T priority patent/ATE188966T1/de
Priority to AU78554/94A priority patent/AU679573B2/en
Priority to NZ274500A priority patent/NZ274500A/en
Priority to SK437-96A priority patent/SK282329B6/sk
Priority to ZA947949A priority patent/ZA947949B/xx
Priority to US08/628,662 priority patent/US5753665A/en
Priority to DK94929537T priority patent/DK0723546T3/da
Priority to HU9600959A priority patent/HUT74580A/hu
Priority to CN94194265A priority patent/CN1040537C/zh
Priority to PCT/EP1994/003364 priority patent/WO1995010521A1/en
Priority to RO96-00795A priority patent/RO117020B1/ro
Priority to CA002173857A priority patent/CA2173857A1/en
Priority to BR9407812A priority patent/BR9407812A/pt
Priority to MYPI94002724A priority patent/MY112110A/en
Priority to TW084103591A priority patent/TW372237B/zh
Priority to BG100485A priority patent/BG62405B1/bg
Priority to NO961435A priority patent/NO306509B1/no
Priority to FI961630A priority patent/FI961630A7/fi
Priority to IN1544MA1996 priority patent/IN182801B/en
Priority to BR1100294-8A priority patent/BR1100294A/pt
Priority to GR20000400175T priority patent/GR3032480T3/el
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
GB939321162A 1993-10-13 1993-10-13 Therapeutic agents Pending GB9321162D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents
IN982MA1994 IN179169B (https=) 1993-10-13 1994-10-11
BR9407812A BR9407812A (pt) 1993-10-13 1994-10-12 Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos
ZA947949A ZA947949B (en) 1993-10-13 1994-10-12 Therapeutic agents
US08/628,662 US5753665A (en) 1993-10-13 1994-10-12 Therapeutic agents
RU96108927A RU2136684C1 (ru) 1993-10-13 1994-10-12 Производные 1,2,4-триазоло [1,5-a]пиримидинов, их фармацевтически приемлемые соли и стереоизомеры, фармацевтическая композиция и способ ингибирования припадков
JP7511287A JPH09503771A (ja) 1993-10-13 1994-10-12 治療剤
DE69422724T DE69422724T2 (de) 1993-10-13 1994-10-12 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN
PT94929537T PT723546E (pt) 1993-10-13 1994-10-12 Blocos primitivos de 1,2,4-triazolo(1,5-a) e a sua utilizacao no tratamento de desordens neurologicas
PL94313970A PL177920B1 (pl) 1993-10-13 1994-10-12 Nowe pochodne 1,2,4-triazolo[1,5-a]pirymidyny, sposób wytwarzania nowych pochodnych 1,2,4-triazolo[1,5-a]pirymidyny, kompozycja farmaceutyczna i sposób wytwarzania kompozycji farmaceutycznej
UA96041428A UA42738C2 (uk) 1993-10-13 1994-10-12 ПОХІДНІ 1,2,4-ТРИАЗОЛО[1,5-а]ПІРИМІДИНІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ НАПАДІВ
ES94929537T ES2142413T3 (es) 1993-10-13 1994-10-12 1,2,4-triazolo(1,5-a)pirimidinas y su uso en el tratamiento de enfermedades neurologicas.
IL111259A IL111259A (en) 1993-10-13 1994-10-12 PHARMACEUTICAL COMPOSITIONS COMPRISING 7-PHENOXY (CYCLO) ALKYL-£1, 2, 4| TRIAZOLO £1, 5-a| PYRIMIDINE DERIVATIVES, SOME NEW SUCH COMPOUNDS AND THEIR PREPARATION
AT94929537T ATE188966T1 (de) 1993-10-13 1994-10-12 1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen
AU78554/94A AU679573B2 (en) 1993-10-13 1994-10-12 Therapeutic agents
NZ274500A NZ274500A (en) 1993-10-13 1994-10-12 7-phenoxyalkyl-1,2,4-triazolo[1,5-a]pyrimidine derivatives; pharmaceutical compositions
SK437-96A SK282329B6 (sk) 1993-10-13 1994-10-12 1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie
EP94929537A EP0723546B1 (en) 1993-10-13 1994-10-12 1,2,4 - TRIZOLO[1,5-a]PYRIMIDINE AND THEIR USE FOR TREATMENT OF NEUROLOGICAL DISORDERS
CZ961069A CZ106996A3 (en) 1993-10-13 1994-10-12 Pharmaceutical composition
DK94929537T DK0723546T3 (da) 1993-10-13 1994-10-12 1,2,4-triazolo[1,5-a]pyrimidin og deres anvendelse til behandling af neurologiske lidelser
HU9600959A HUT74580A (en) 1993-10-13 1994-10-12 Triazolo[1,5-a]pyrimidine derivatives, proless for producing them and pharmaceutical compositions containing them
CN94194265A CN1040537C (zh) 1993-10-13 1994-10-12 取代的1,2.4－三唑并[1,5－a]嘧啶类其制备方法以及含有它的药物组合物
PCT/EP1994/003364 WO1995010521A1 (en) 1993-10-13 1994-10-12 Therapeutic agents
RO96-00795A RO117020B1 (ro) 1993-10-13 1994-10-12 DERIVATI DE 1,2,4-TRIAZOL [1,5-a]PIRIMIDINA SI PROCEDEU DE OBTINERE A ACESTORA
CA002173857A CA2173857A1 (en) 1993-10-13 1994-10-12 Therapeutic agents
MYPI94002724A MY112110A (en) 1993-10-13 1994-10-13 Novel 1,2,4-triazolo [1,5 a] pyrimidine compounds, their pharmaceutical compositions and use in the treatment of neurological disorders,and processes for their preparation.
TW084103591A TW372237B (en) 1993-10-13 1995-04-12 1-2-4 triazolo[1,5-a]pyrimidines, pharmaceutical compositions containing them for treatment and/or prophylaxis of seizures, neurological disorders and/or conditions in which there is neurological damage, and processes for their preparation
BG100485A BG62405B1 (bg) 1993-10-13 1996-04-09 Терапевтични средства
NO961435A NO306509B1 (no) 1993-10-13 1996-04-11 Pyrimidinderivater, anvendelse derav og farmasöytisk preparat
FI961630A FI961630A7 (fi) 1993-10-13 1996-04-12 Terapeuttisia aineita
IN1544MA1996 IN182801B (https=) 1993-10-13 1996-09-04
BR1100294-8A BR1100294A (pt) 1993-10-13 1997-04-18 Compostos, composição farmacêutica, uso de compostos, e, processo para a preparação de compostos
GR20000400175T GR3032480T3 (en) 1993-10-13 2000-01-26 1,2,4 - Triazolo (1,5-a) pyrimitives and their use for treatment of neurological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB9321162D0 true GB9321162D0 (en) 1993-12-01

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939321162A Pending GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents

Country Status (31)

Country Link
US (1) US5753665A (https=)
EP (1) EP0723546B1 (https=)
JP (1) JPH09503771A (https=)
CN (1) CN1040537C (https=)
AT (1) ATE188966T1 (https=)
AU (1) AU679573B2 (https=)
BG (1) BG62405B1 (https=)
BR (1) BR9407812A (https=)
CA (1) CA2173857A1 (https=)
CZ (1) CZ106996A3 (https=)
DE (1) DE69422724T2 (https=)
DK (1) DK0723546T3 (https=)
ES (1) ES2142413T3 (https=)
FI (1) FI961630A7 (https=)
GB (1) GB9321162D0 (https=)
GR (1) GR3032480T3 (https=)
HU (1) HUT74580A (https=)
IL (1) IL111259A (https=)
IN (1) IN179169B (https=)
MY (1) MY112110A (https=)
NO (1) NO306509B1 (https=)
NZ (1) NZ274500A (https=)
PL (1) PL177920B1 (https=)
PT (1) PT723546E (https=)
RO (1) RO117020B1 (https=)
RU (1) RU2136684C1 (https=)
SK (1) SK282329B6 (https=)
TW (1) TW372237B (https=)
UA (1) UA42738C2 (https=)
WO (1) WO1995010521A1 (https=)
ZA (1) ZA947949B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
KR20000029548A (ko) 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
GB9617727D0 (en) * 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19707008A1 (de) 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
ATE371659T1 (de) * 1998-10-16 2007-09-15 Merck Sharp & Dohme Pyrazolotriazinderivate als gaba-rezeptorliganden
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
GEP20053688B (en) * 2000-06-30 2005-12-12 Wyeth Corp Substituted-Triazolopyrimidines as Anticancer Agents
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
CA2554696C (en) 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
JP2007533726A (ja) 2004-04-22 2007-11-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
CN104098578A (zh) 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
US20120095025A1 (en) * 2009-04-01 2012-04-19 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US8765770B2 (en) 2009-04-01 2014-07-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
DK0723546T3 (da) 2000-05-01
DE69422724T2 (de) 2000-09-07
FI961630A0 (fi) 1996-04-12
IL111259A0 (en) 1995-03-30
DE69422724D1 (de) 2000-02-24
PL177920B1 (pl) 2000-01-31
CN1040537C (zh) 1998-11-04
NZ274500A (en) 1997-06-24
EP0723546B1 (en) 2000-01-19
US5753665A (en) 1998-05-19
HU9600959D0 (en) 1996-06-28
AU7855494A (en) 1995-05-04
AU679573B2 (en) 1997-07-03
BG100485A (bg) 1996-11-29
UA42738C2 (uk) 2001-11-15
RU2136684C1 (ru) 1999-09-10
GR3032480T3 (en) 2000-05-31
ATE188966T1 (de) 2000-02-15
WO1995010521A1 (en) 1995-04-20
BR9407812A (pt) 1997-05-06
IL111259A (en) 1998-02-08
RO117020B1 (ro) 2001-09-28
EP0723546A1 (en) 1996-07-31
NO961435L (no) 1996-06-10
SK43796A3 (en) 1996-10-02
NO306509B1 (no) 1999-11-15
CA2173857A1 (en) 1995-04-20
CZ106996A3 (en) 1996-09-11
FI961630A7 (fi) 1996-04-12
IN179169B (https=) 1997-09-06
HUT74580A (en) 1997-01-28
TW372237B (en) 1999-10-21
CN1135754A (zh) 1996-11-13
SK282329B6 (sk) 2002-01-07
JPH09503771A (ja) 1997-04-15
ZA947949B (en) 1996-01-23
ES2142413T3 (es) 2000-04-16
PL313970A1 (en) 1996-08-05
PT723546E (pt) 2000-04-28
NO961435D0 (no) 1996-04-11
MY112110A (en) 2001-04-30
BG62405B1 (bg) 1999-10-29

Similar Documents

Publication Publication Date Title
GB9321162D0 (en) Therapeutic agents
PL308757A1 (en) Therapeutic agents
PL309347A1 (en) Application of anticonvulsive agents in therapy of neurological damages caused by or associated with injuries
IL118836A0 (en) Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan
HU9202429D0 (en) Method for producing amidic compounds and pharmaceutical prepartives containing said compounds as active agents
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CA2148194A1 (en) Cyclopeptides of the formula i
GB9418912D0 (en) Pharmaceutically active compounds
ZA943241B (en) Therapeutic agents
TW359667B (en) Tetralines
JO1833B1 (en) Therapeutic agents
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
CA2162706A1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease